Sutro Biopharma (NASDAQ:STRO - Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a "strong sell" rating to a "sell" rating in a report released on Monday, Wall Street Zen reports.
Other equities analysts have also issued research reports about the stock. Wells Fargo & Company assumed coverage on shares of Sutro Biopharma in a research report on Wednesday, September 30th. They set an "overweight" rating and a $49.00 price target for the company. Wedbush reaffirmed an "outperform" rating and issued a $60.00 price objective on shares of Sutro Biopharma in a research report on Thursday, October 15th. Mizuho raised shares of Sutro Biopharma to a "strong-buy" rating in a research report on Wednesday, September 16th. Barclays boosted their target price on shares of Sutro Biopharma from $56.00 to $57.00 and gave the company an "overweight" rating in a research note on Friday. Finally, HC Wainwright reissued a "buy" rating on shares of Sutro Biopharma in a research report on Friday, October 16th. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Sutro Biopharma presently has an average rating of "Buy" and an average price target of $49.60.
Get Our Latest Stock Analysis on Sutro Biopharma
Sutro Biopharma Price Performance
Shares of NASDAQ:STRO opened at $9.82 on Monday. The company has a market capitalization of $162.82 million, a PE ratio of -0.82 and a beta of 1.56. The business has a fifty day moving average price of $13.18 and a two-hundred day moving average price of $22.54. Sutro Biopharma has a 1 year low of $7.15 and a 1 year high of $43.85.
Sutro Biopharma (NASDAQ:STRO - Get Free Report) last announced its earnings results on Thursday, November 12th. The company reported ($1.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.64) by ($0.26). The firm had revenue of $9.10 million during the quarter, compared to analysts' expectations of $14.11 million. Sell-side analysts anticipate that Sutro Biopharma will post -8.12 earnings per share for the current year.
Institutional Investors Weigh In On Sutro Biopharma
Institutional investors and hedge funds have recently modified their holdings of the company. Affinity Asset Advisors LLC grew its stake in Sutro Biopharma by 42.9% during the first quarter. Affinity Asset Advisors LLC now owns 1,069,519 shares of the company's stock valued at $26,642,000 after acquiring an additional 321,137 shares in the last quarter. Orbimed Advisors LLC purchased a new stake in Sutro Biopharma in the 1st quarter worth approximately $19,956,000. Perceptive Advisors LLC purchased a new stake in Sutro Biopharma in the 1st quarter worth approximately $17,818,000. ADAR1 Capital Management LLC lifted its stake in Sutro Biopharma by 681.8% in the 1st quarter. ADAR1 Capital Management LLC now owns 524,441 shares of the company's stock worth $13,064,000 after purchasing an additional 457,364 shares in the last quarter. Finally, Marshall Wace LLP boosted its holdings in Sutro Biopharma by 81.4% in the 3rd quarter. Marshall Wace LLP now owns 317,964 shares of the company's stock valued at $5,122,000 after purchasing an additional 142,718 shares during the period. 96.99% of the stock is owned by hedge funds and other institutional investors.
Sutro Biopharma Company Profile
(
Get Free Report)
Sutro Biopharma is a biotechnology company focused on discovering and developing targeted cancer treatments. Its research has centered on antibody-drug conjugates (ADCs), which use antibodies to deliver cancer-fighting drugs to selected cells. The company developed its XpressCF+ platform, a cell-free protein synthesis and site-specific conjugation technology intended to support the design and production of biologic medicines. Sutro's clinical-stage programs have included luveltamab tazevibulin, an ADC targeting folate receptor alpha, and STRO-003, an ADC targeting ROR1.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Sutro Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sutro Biopharma wasn't on the list.
While Sutro Biopharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.